284 related articles for article (PubMed ID: 23319521)
1. IOM Review of FDA--approved biologics labeled or studied for pediatric use.
Field MJ; Ellinger LK; Boat TF
Pediatrics; 2013 Feb; 131(2):328-35. PubMed ID: 23319521
[TBL] [Abstract][Full Text] [Related]
2. Regulations requiring manufacturers to assess the safety and effectiveness of new drugs and biological products in pediatric patients--FDA. Final rule.
Fed Regist; 1998 Dec; 63(231):66631-72. PubMed ID: 10338880
[TBL] [Abstract][Full Text] [Related]
3. Regulatory issues in pediatric psychopharmacology.
Laughren TP
J Am Acad Child Adolesc Psychiatry; 1996 Oct; 35(10):1276-82. PubMed ID: 8885581
[TBL] [Abstract][Full Text] [Related]
4. Medicines for children licensed by the European Agency for the Evaluation of Medicinal Products.
Ceci A; Felisi M; Catapano M; Baiardi P; Cipollina L; Ravera S; Bagnulo S; Reggio S; Rondini G
Eur J Clin Pharmacol; 2002 Nov; 58(8):495-500. PubMed ID: 12451425
[TBL] [Abstract][Full Text] [Related]
5. Supplemental applications proposing labeling changes for approved drugs, biologics, and medical devices. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2008 Aug; 73(164):49603-10. PubMed ID: 18958946
[TBL] [Abstract][Full Text] [Related]
6. Prescribing medications in pediatrics: concerns regarding FDA approval and pharmacokinetics.
Novak E; Allen PJ
Pediatr Nurs; 2007; 33(1):64-70. PubMed ID: 17411005
[TBL] [Abstract][Full Text] [Related]
7. Impact of new regulations for pediatric labeling by the Food and Drug Administration.
Buck ML
Pediatr Nurs; 2000; 26(1):95-6. PubMed ID: 12026326
[No Abstract] [Full Text] [Related]
8. Uses of drugs not described in the package insert (off-label uses).
Committee on Drugs. American Academy of Pediatrics
Pediatrics; 2002 Jul; 110(1 Pt 1):181-3. PubMed ID: 12093968
[TBL] [Abstract][Full Text] [Related]
9. Dissemination of information on unapproved/new uses for marketed drugs, biologics, and devices--FDA. Final rule.
Fed Regist; 1998 Nov; 63(224):64556-88. PubMed ID: 10339052
[TBL] [Abstract][Full Text] [Related]
10. US FDA review and regulation of preventive vaccines for infectious disease indications: impact of the FDA Amendments Act 2007.
Gruber MF
Expert Rev Vaccines; 2011 Jul; 10(7):1011-9. PubMed ID: 21806396
[TBL] [Abstract][Full Text] [Related]
11. Pediatric testing of prescription drugs: the Food and Drug Administration's carrot and stick for the pharmaceutical industry.
Karst KR
Am Univ Law Rev; 2000; 49():739-72. PubMed ID: 11067732
[No Abstract] [Full Text] [Related]
12. The Best Pharmaceuticals for Children Act of 2002: the rise of the voluntary incentive structure and congressional refusal to require pediatric testing.
Breslow LH
Harvard J Legis; 2003; 40(1):133-93. PubMed ID: 16594116
[TBL] [Abstract][Full Text] [Related]
13. FDA Modernization Act: implications for oncology.
Morris L
Oncology (Williston Park); 1998 Nov; 12(11A):139-41. PubMed ID: 10028506
[TBL] [Abstract][Full Text] [Related]
14. Adolescent dosing and labeling since the Food and Drug Administration Amendments Act of 2007.
Momper JD; Mulugeta Y; Green DJ; Karesh A; Krudys KM; Sachs HC; Yao LP; Burckart GJ
JAMA Pediatr; 2013 Oct; 167(10):926-32. PubMed ID: 23921678
[TBL] [Abstract][Full Text] [Related]
15. Pediatric exclusivity: evolving legislation and novel complexities within pediatric therapeutic development.
Rivera DR; Hartzema AG
Ann Pharmacother; 2014 Mar; 48(3):369-79. PubMed ID: 24311725
[TBL] [Abstract][Full Text] [Related]
16. Food and Drug Administration approval for medications used in the pediatric intensive care unit: a continuing conundrum.
Yang CP; Veltri MA; Anton B; Yaster M; Berkowitz ID
Pediatr Crit Care Med; 2011 Sep; 12(5):e195-9. PubMed ID: 21057369
[TBL] [Abstract][Full Text] [Related]
17. The globalization of pediatric clinical trials.
Dunne J; Murphy MD; Rodriguez WJ
Pediatrics; 2012 Dec; 130(6):e1583-91. PubMed ID: 23129087
[TBL] [Abstract][Full Text] [Related]
18. The impact of the written request process on drug development in childhood cancer.
Snyder KM; Reaman G; Avant D; Pazdur R
Pediatr Blood Cancer; 2013 Apr; 60(4):531-7. PubMed ID: 23335552
[TBL] [Abstract][Full Text] [Related]
19. The National Institutes of Health and the Best Pharmaceuticals for Children Act.
Zajicek A
Paediatr Drugs; 2009; 11(1):45-7. PubMed ID: 19127953
[TBL] [Abstract][Full Text] [Related]
20. Unapproved uses of approved drugs: the physician, the package insert, and the Food and Drug Administration: subject review. American Academy of Pediatrics Committee on Drugs.
Pediatrics; 1996 Jul; 98(1):143-5. PubMed ID: 8668390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
